Author:
Janson A. M.,Møller A.,Hedlund P. B.,von Euler G.,Fuxe K.
Reference25 articles.
1. Marsden CD.: Parkinson’s disease. Lancet 1990; 335: 948–952.
2. Baron JA.: Cigarette smoking and Parkinson’s disease. Neurology 1986; 36: 1490–1496.
3. Janson AM, Fuxe K, Agnati LF, Kitayama I, Härfstrand A, Andersson K, Goldstein M.: Chronic nicotine treatment counteracts the disappearance oftyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 1988; 455: 332–345.
4. Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF.: Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection, Naunyn-Schmiedeberg’s Arch. Pharmacol. 1990; 341: 171–181.
5. Janson AM, Meana JJ, Goiny M, Herrera-Marschitz M.: Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the meso-diencephalic junction in rats: a microdialysis study. Neurosci. Lett. 1991; 134: 88–92.